CELGZ News Alert Celgene Corp (CELGZ) 3.34 12/25/2014 12:42:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELGZ) 3.34 $CELGZ

Celgene Receives Positive CHMP Opinion to Extend REVLIMID(R) (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant
Business Wire - Fri Dec 19, 7:10AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for continuous oral treatment with REVLIMID(R) in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation.
CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)

Celgene Corporation Earns CEO Cancer Gold Standard Accreditation
Business Wire - Thu Dec 18, 6:00AM CST
Celgene Corporation, a global biopharmaceutical company headquartered in Summit, New Jersey, has earned the prestigious global CEO Cancer Gold Standard(TM) accreditation. This accreditation recognizes the Company's worldwide commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring broad access to innovative cancer therapies that are extending lives, improving quality of life and increasing productivity for employees and their family members around the globe.
CELGZ: 3.34 (-0.01)

Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 91.29 (+1.84), ICPT: 151.49 (+5.85), TBRA: (), CELGZ: 3.34 (-0.01)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)

Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.49 (unch), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), CLDX: 17.08 (-0.18), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06), PVCT: 0.85 (-0.02), VICL: 1.03 (+0.02), AZN: 70.44 (+0.26), DCTH: 1.36 (+0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)

Flexus Biosciences, a Cancer Immunotherapy Company Focused on Agents for the Reversal of Tumor Immunosuppression (ARTIS), Announces $38M Financing
GlobeNewswire - Wed Dec 17, 8:35AM CST
Financing Led by Kleiner Perkins Caufield & Byers, The Column Group and Celgene
CELGZ: 3.34 (-0.01)

Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 4.41 (+0.13), NVAX: 5.81 (+0.18), AMRN: 0.99 (unch), AEZS: 0.59 (-0.02), CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)

Research and Markets: Global Multiple Myeloma Drugs Market 2015-2019 with Celgene, J & J, Novartis, Onyx Pharmaceuticals, Sanofi & Takeda Pharmaceutical Dominating
Business Wire - Tue Dec 16, 2:48PM CST
Research and Markets (http://www.researchandmarkets.com/research/cj2jb5/global_multiple) has announced the addition of the "Global Multiple Myeloma Drugs Market 2015-2019" report to their offering.
CELGZ: 3.34 (-0.01)

Biotech Weekly: Top Ideas From The San Antonio Breast Cancer Symposium
Daniel Ward - Seeking Alpha - Tue Dec 16, 10:00AM CST
Approaching 7,500 scientists, advocates, professors, and healthcare professional descended upon the San Antonio Riverwalk to present and discuss groundbreaking research in the field of breast cancer at the San Antonio Breast Cancer Symposium (SABCS)...
ONTY: 1.89 (+0.01), CELGZ: 3.34 (-0.01), CELG: 109.60 (+3.48)

Global Multiple Myeloma Drugs Market 2015-2019 with Celgene, J & J, Novartis, Onyx Pharmaceuticals, Sanofi & Takeda Pharmaceutical Dominating
M2 - Tue Dec 16, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qwb87/global_multiple) has announced the addition of the "Global Multiple Myeloma Drugs Market 2015-2019" report to their offering. The Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50% over the period 2014-2019 This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. One of the major trends being witnessed in this market is increased awareness about multiple myeloma among the medical fraternity, patients, and the families of patients, which enhances the number of treatment-seeking patients, which results in an increase in the overall consumption of medicines. According to the report, an increase in the presence of unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, and hence the mortality rate is high. Therefore, drugs that can cause disease remission in patients are expected to drive the growth of the market. Further, the report states that the high cost of treatment is one of the major challenges hindering the growth of the market. Drugs used for the treatment of cancer are expensive and hence get a poor response from patients. The patients also tend to withdraw from expensive treatment regimens. Key Vendors - Celgene - Johnson & Johnson - Novartis - Onyx Pharmaceuticals - Sanofi - Takeda Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Market Segmentation by Route of Administration - Market Segmentation by Dosage Form - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Portfolio - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7q...l_multiple
JNJ: 104.59 (+0.31), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Global Oncology Market - Trends, Forecast and Pipeline Analysis 2014-2020 - Market is Poised to Grow to $109 Billion by 2020
M2 - Tue Dec 16, 8:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c69h6/global_oncology) has announced the addition of the "Global Oncology Market - Trends, Forecast and Pipeline Analysis" report to their offering. Cancer, with a death toll exceeding that of AIDS (Acquired Immune Deficiency Syndrome), tuberculosis and malaria collectively, accounted for 8.3 million deaths in 2013. With a skyrocketing incidence of 469.6 per 100,000 in the US alone, the oncology market is poised to grow at a substantial CAGR of around seven percent to $109 billion by 2020. Targeted therapy class is the top dog' among all therapy segments with nearly 3x the combined market of cytotoxic and hormonal therapy. Growth factors such as EGF (Epidermal Growth Factors) and VEGF govern around half of the oncology therapy market, and have changed the landscape of pipeline and LCM (Life Cycle Management) strategies, outstripping the orthodox indications approach, said analyst Hardik Sharma. Although in last two years, a plethora of targeted drugs has been launched and is in development, price pressures have started popping up due to high scrutiny from payers, physicians and governments. With almost every drug growing annually above 10%, Roche is the market leader and front-runner in life-cycle management of oncology drugs, as it holds the highest number of in-line extensions (ILEs), which comprise around half of its entire pipeline. The words of Roche CEO Severin SchwanWe go where the science takes usdemonstrates its focus on bolt-on acquisitions compared with a transformational approach. Celgene also shares the same philosophy as evident from its recent deal with OncoMed. Avastin is the leader with sales of $6.7 billion in 2013 and in the short- to mid-term it is forecast to sustain its position supported by its extensive pipeline and entrenched indications base. Meanwhile, in the long term, Revlimid is expected to dominate due to its extensive pipeline, prolonged patent term and impressive CAGR of more than 40%. Key Topics Covered: 1. Charts & Tables 2. Market at a Glance - Global and Regional levels (NA, EU, APAC) 3. Introduction to Cancer (20 major cancers) 4. Market Overview 5. Global Oncology Market Forecast 6. Top Oncology Brands - Detailed Insight 7. Market Dynamics 8. Pipeline Analysis and Interpretation 9. Company Profiles 10. Competitive Landscape & Value Chain 11. Recent developments 12. Appendix 13. Research Methodology 14. Disclaimer Companies Mentioned - AbbVie - Amgen - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb - Celgene Corporation - Eli Lilly and Company - F. Hoffmann-La Roche AG - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pfizer, Inc - Sanofi S.A. For more information visit http://www.researchandmarkets.com/research/4c...l_oncology
JNJ: 104.59 (+0.31), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Sarcoidosis and Myotonic Dystrophy Therapeutic Pipeline Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Mon Dec 15, 4:30PM CST
The report "Sarcoidosis and Myotonic Dystrophy Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Sarcoidosis and Myotonic Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and Myotonic Dystrophy and special features on late-stage and discontinued projects.
CELGZ: 3.34 (-0.01)

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.41 (+0.13), PCYC: 121.84 (+1.15), TGTX: 16.03 (+0.33), ONTX: 3.82 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86), INFI: 16.65 (+0.37), CELGZ: 3.34 (-0.01), NVS: 93.91 (+0.66)

Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13), RDHL: 12.22 (-0.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), ARGS: 9.65 (+0.34), NVO: 43.80 (+1.08), IDRA: 3.89 (+0.02), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), CBMG: 12.98 (+0.19), CELGZ: 3.34 (-0.01)

T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 16.65 (+0.37), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), KPTI: 37.78 (+1.28), CELGZ: 3.34 (-0.01)

Global Lung Cancer Therapeutics Market 2015-2019: Key Vendors are AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche and Pfizer
PR Newswire Europe - Wed Dec 10, 8:07AM CST
DUBLIN, Dec. 09, 2014 /PRNewswire/ --Research and Markets
LLY: 70.16 (+0.42), CELGZ: 3.34 (-0.01)

Northern Biologics to Develop Antibody Therapeutics in Toronto
CNW Group - Wed Dec 10, 7:00AM CST
Collaboration between Versant Ventures and leading Canadian research institutes spawns new biotech company
CELGZ: 3.34 (-0.01)

Versant Ventures Closes $305 Million Healthcare Fund
Business Wire - Wed Dec 10, 6:30AM CST
Versant Ventures, a global healthcare investment firm, today announced the close of Versant Venture Capital V L.P. at $305 million and in excess of the initial fund target of $250 million. Since its inception, Versant has raised $1.9 billion to invest in innovative biopharmaceutical, medical device, and healthcare services/HCIT companies. The firm invests from offices in North America and Europe, and it has assembled a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building.
CELGZ: 3.34 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Organon & Co. Class Action Lawsuit: Key Details You Should Know

Updated Category News Views 221

Overview of the Class Action Lawsuit Against Organon & Co. The latest developments in the class action lawsuit regarding Organon & Co. (NYSE: OGN) have attracted attention from investors. The lawsuit is aimed at representing purchasers of Organon's publicly traded securities during a specific time frame. Robbins Geller Rudman & Dowd LLP has taken the lead in filing this...

Continue Reading
JINRO Partners with BTS's V: A Strategic Move

Updated Category News Views 25

What's Brewing Between JINRO and BTS's V? Picture this: you're wandering the aisles of an international market, see a splashy new bottle of soju, and notice V from BTS smiling from the label. That's right, folks, JINRO, the world's reigning soju brand, has just snagged a partnership with BTS's V to serve up a global brand punch. This move isn't just a pretty face on a...

Continue Reading
Latin Metals Unveils Exciting Spin-Out Plan for Copper Assets

Updated Category News Views 172

Latin Metals Moves Forward with Spin-Out of Peruvian Assets Latin Metals Inc. (TSXV: LMS, OTCQB: LMSQF) is charting a new course by announcing its decision to spin-out certain Peruvian exploration projects into a newly founded subsidiary named Latin Explore. This strategic move aims to unlock value for shareholders while maintaining a robust exploration agenda. Overview...

Continue Reading
McCormick's Resilience Shines Amidst Economic Challenges

Updated Category News Views 66

McCormick Challenges and Growth Strategy McCormick & Company, Inc. (NASDAQ: MKC) recently announced its third-quarter earnings, revealing a solid financial performance, even in a tough consumer environment. The company achieved a 1% volume growth in its Consumer segment and steady sales in its Flavor Solutions segment, showcasing a strong market presence despite...

Continue Reading
Goodyear's Financial Performance Amidst Industry Challenges

Updated Category News Views 248

Understanding Goodyear's Recent Earnings Report Goodyear Tire & Rubber Co (NASDAQ: GT) has reported its recent financial results, particularly highlighting the challenges faced during the second quarter of their fiscal year 2025. This period proved to be quite turbulent after the closing bell, reflecting considerable disruptions in their operating environment that...

Continue Reading